Is 4D Molecular Therapeutics Inc. (NASDAQ: FDMT) Stock On Course For Another Boom Or Bust? – Marketing Sentinel
Home  »  Technologies   »  Is 4D Molecular Therapeutics Inc. (NASDAQ: FDMT) S...

Is 4D Molecular Therapeutics Inc. (NASDAQ: FDMT) Stock On Course For Another Boom Or Bust?

During the last session, 4D Molecular Therapeutics Inc. (NASDAQ:FDMT)’s traded shares were 0.41 million. At the end of the trading day, the stock’s price was $9.01, reflecting an intraday loss of -4.35% or -$0.41. The 52-week high for the FDMT share is $36.14, that puts it down -301.11 from that peak though still a striking -0.55% loss since the share price plummeted to a 52-week low of $9.06. The company’s market capitalization is $303.46M, and the average intraday trading volume over the past 10 days was 0.23 million shares, and the average trade volume was 198.38K shares over the past three months.

4D Molecular Therapeutics Inc. (FDMT) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.00. FDMT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.86.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

4D Molecular Therapeutics Inc. (NASDAQ:FDMT) trade information

4D Molecular Therapeutics Inc. (FDMT) registered a -4.35% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.35% in intraday trading to $9.01 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -14.43%, and it has moved by -35.04% in 30 days. Based on these gigs, the overall price performance for the year is -66.00%. The short interest in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is 0.85 million shares and it means that shorts have 3.45 day(s) to cover.

The consensus price target of analysts on Wall Street is $28.25, which implies an increase of 68.11% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18.00 and $37.00 respectively. As a result, FDMT is trading at a discount of -310.65% off the target high and -99.78% off the low.

4D Molecular Therapeutics Inc. (FDMT) estimates and forecasts

Statistics show that 4D Molecular Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. 4D Molecular Therapeutics Inc. (FDMT) shares have gone down -63.63% during the last six months, with a year-to-date growth rate less than the industry average at -12.06% against 9.40. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 63.60% this quarter and then drop -82.00% in the quarter after that. In the rating firms’ projections, revenue will increase 34.40% compared to the previous financial year.

Revenue for the current quarter is expected to be $350k as predicted by 2 analyst(s).

While earnings are projected to return -21.00% in 2022, the next five years will return 35.70% per annum.

FDMT Dividends

4D Molecular Therapeutics Inc. is due to release its next quarterly earnings between March 23 and March 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

4D Molecular Therapeutics Inc. (NASDAQ:FDMT)’s Major holders

4D Molecular Therapeutics Inc. insiders own 9.57% of total outstanding shares while institutional holders control 69.09%, with the float percentage being 76.40%. Viking Global Investors, L.P. is the largest shareholder of the company, while 114 institutions own stock in it. As of Sep 29, 2021, the company held over 3.94 million shares (or 12.25% of all shares), a total value of $106.21 million in shares.

The next largest institutional holding, with 2.01 million shares, is of BVF Inc.’s that is approximately 6.24% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $54.1 million.

Also, the Mutual Funds coming in first place with the largest holdings of 4D Molecular Therapeutics Inc. (FDMT) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.51 million shares. This amounts to just over 1.58 percent of the company’s overall shares, with a $13.74 million market value. The same data shows that the other fund manager holds slightly less at 0.49 million, or about 1.51% of the stock, which is worth about $11.66 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts